NCT03808558View on ClinicalTrials.gov

Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

April 3, 2025

Study Completion Date

December 1, 2026

Conditions
KRAS Gene Mutation
Interventions
DRUG

TVB-2640

TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.

Trial Locations (2)

45267

University of Cincinnati, Cincinnati

75390-9179

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

Sagimet Biosciences Inc.

INDUSTRY

collaborator

Cancer Prevention Research Institute of Texas

OTHER

collaborator

Gateway for Cancer Research

OTHER

lead

David E Gerber

OTHER